FDA Updates Naloxegol Labeling for Opioid-Induced Constipation to Include Prior Cancer Indication

The FDA has updated the indication of naloxegol (Movantik, AstraZeneca) tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic noncancer pain to include patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

This label update follows initial FDA approval for naloxegol in 2014 as the first once-daily oral peripherally acting mu-opioid receptor antagonist medication for the